Therapy Areas: Oncology
Mirati Therapeutics names Faheem Hasnain as board chairman
20 February 2019 -

Oncology company Mirati Therapeutics Inc (NASDAQ:MRTX) revealed on Tuesday the election of Faheem Hasnain as chairman of the board with effect from 15 February 2019.

In conjunction, Dr Rodney Lappe PhD will step down as board chairman and will not seek re-election at the company's 2019 annual meeting of shareholders,but will continue as a consulting advisor after his board tenure ends.

Currently, Hasnain serves as the executive chairman of Gossamer Bio Inc, focused on the discovery and development of novel and differentiated therapeutic products.

Recently, Hasnain has worked as president, chief executive officer and director of Receptos Inc from November 2010 to August 2015 as well as president and chief executive officer and director of Facet Biotech Corporation from December 2008 until its acquisition in April 2010.

Previously, Hasnain was employed as president, chief executive officer and director of PDL BioPharma Inc, executive vice president of the oncology/rheumatology strategic business unit at Biogen Idec Inc, president of the Oncology Therapeutics Network at Bristol-Myers Squibb as well as part of GlaxoSmithKline and its predecessor.

Login
Username:

Password: